Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileKeith Thomas Flaherty, M.D.

TitleProfessor of Medicine
InstitutionMassachusetts General Hospital
DepartmentMedicine
AddressMassachusetts General Hospital
Yawkey-7, Hem/Onc
55 Fruit St
Boston MA 02114
Phone617/732-6510
Fax617/975-0985
vCardDownload vCard (login for email)

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
UM1CA186709     (KUFE, DONALD W.)Mar 13, 2014 - Feb 28, 2019
NIH/NCI
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis
Role: Principal Investigator

U54CA163125     (FUTREAL, ANDREW ANDREW)Sep 21, 2011 - Jul 31, 2016
NIH/NCI
Role of Tumor Stroma in Therapeutic Response and Resistance
Role: Principal Investigator

R01CA135509     (LEE, WILLIAM M)Jul 1, 2009 - May 31, 2014
NIH/NCI
Genotype and phenotype predictors in therapy response in renal cell carcinoma
Role: Principal Investigator

K23CA104884     (FLAHERTY, KEITH T)Sep 17, 2004 - Aug 31, 2009
NIH/NCI
Combination Strategies for Angiogenesis Inhibition
Role: Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017 Sep; 83:247-257. PMID: 28756137.
    View in: PubMed
  2. Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT, Wargo JA, Wellbrock C. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med. 2017 Aug; 9(8):1011-1029. PMID: 28606996.
    View in: PubMed
  3. Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. Clin Cancer Res. 2017 Jul 19. PMID: 28724666.
    View in: PubMed
  4. Izar B, Sharfman W, Hodi FS, Lawrence D, Flaherty KT, Amaravadi R, Kim KB, Puzanov I, Sosman J, Dummer R, Goldinger SM, Lam L, Kakar S, Tang Z, Krieter O, McDermott DF, Atkins MB. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Med. 2017 Aug; 6(8):1904-1914. PMID: 28719152.
    View in: PubMed
  5. Kraft S, Fernandez-Figueras MT, Richarz NA, Flaherty KT, Hoang MP. PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression. J Am Acad Dermatol. 2017 Sep; 77(3):534-542. PMID: 28728868.
    View in: PubMed
  6. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017 Jul 01; 28(7):1631-1639. PMID: 28475671.
    View in: PubMed
  7. Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer. 2017 Sep; 82:45-55. PMID: 28648698.
    View in: PubMed
  8. Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017 Jul; 18(7):863-873. PMID: 28592387.
    View in: PubMed
  9. Betof AS, Nipp RD, Giobbie-Hurder A, Johnpulle RAN, Rubin K, Rubinstein SM, Flaherty KT, Lawrence DP, Johnson DB, Sullivan RJ. Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. Oncologist. 2017 Aug; 22(8):963-971. PMID: 28476944.
    View in: PubMed
  10. Zhang D, Zhang G, Hu X, Wu L, Feng Y, He S, Zhang Y, Hu Z, Yang L, Tian T, Xu W, Wei Z, Lu Y, Flaherty KT, Zhong X, Mills GB, Gimotty PA, Xu X, Herlyn M, Zhang L. Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Res. 2017 Jul 15; 77(14):3745-3757. PMID: 28473531.
    View in: PubMed
  11. Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty K, Boland G, Mahmood U. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Res. 2017 May 01; 77(9):2318-2327. PMID: 28461564.
    View in: PubMed
  12. Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, Acosta JC, Kamarashev J, Frederick DT, Cooper ZA, Reuben A, Gil J, Flaherty KT, Wargo JA, Vermi W, Smith MP, Wellbrock C, Hurlstone A. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J Exp Med. 2017 Jun 05; 214(6):1691-1710. PMID: 28450382.
    View in: PubMed
  13. Friedman AA, Xia Y, Trippa L, Le LP, Igras V, Frederick DT, Wargo JA, Tanabe KK, Lawrence DP, Neuberg DS, Flaherty KT, Fisher DE. Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clin Cancer Res. 2017 Aug 15; 23(16):4680-4692. PMID: 28446504.
    View in: PubMed
  14. Koetz-Ploch L, Hanniford D, Dolgalev I, Sokolova E, Zhong J, Díaz-Martínez M, Bernstein E, Darvishian F, Flaherty KT, Chapman PB, Tawbi H, Hernando E. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell Melanoma Res. 2017 May; 30(3):328-338. PMID: 28140520.
    View in: PubMed
  15. Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, Mercatanti A, Comelli L, Gurrieri S, Wu LW, Ope O, Flaherty K, Boland GM, Hammond MR, Kwong L, Chiariello M, Stecca B, Zhang G, Salvetti A, Angeloni D, Pitto L, Calorini L, Chiorino G, Pellegrini M, Herlyn M, Osman I, Poliseno L. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 2017 Apr 11; 8(15):25395-25417. PMID: 28445987.
    View in: PubMed
  16. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017 Aug; 14(8):463-482. PMID: 28374786.
    View in: PubMed
  17. Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP. Academic Cancer Center Phase I Program Development. Oncologist. 2017 Apr; 22(4):369-374. PMID: 28314841.
    View in: PubMed
  18. Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017 Mar 09. PMID: 28278333.
    View in: PubMed
  19. Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep. 2017 Mar 09; 7:44123. PMID: 28276530.
    View in: PubMed
  20. Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr; 18(4):435-445. PMID: 28284557.
    View in: PubMed
  21. Flaherty KT, Le DT, Lemery S. Tissue-Agnostic Drug Development. Am Soc Clin Oncol Educ Book. 2017; 37:222-230. PMID: 28561648.
    View in: PubMed
  22. Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016 Dec; 17(12):1743-1754. PMID: 27864013.
    View in: PubMed
  23. Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 08; 7(45):74380-74392. PMID: 27602582.
    View in: PubMed
  24. Trusheim MR, Shrier AA, Antonijevic Z, Beckman RA, Campbell RK, Chen C, Flaherty KT, Loewy J, Lacombe D, Madhavan S, Selker HP, Esserman LJ. PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms. Clin Pharmacol Ther. 2016 Dec; 100(6):713-729. PMID: 27643536.
    View in: PubMed
  25. Khalil DN, Postow MA, Ibrahim N, Ludwig DL, Cosaert J, Kambhampati SR, Tang S, Grebennik D, Kauh JS, Lenz HJ, Flaherty KT, Hodi FS, Lawrence DP, Wolchok JD. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res. 2016 Nov 01; 22(21):5204-5210. PMID: 27797971.
    View in: PubMed
  26. Scarlett UK, Chang DC, Murtagh TJ, Flaherty KT. High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has Come. Cancer Discov. 2016 Sep; 6(9):956-62. PMID: 27587468.
    View in: PubMed
  27. Lawrence NF, Hammond MR, Frederick DT, Su Y, Dias-Santagata D, Deng A, Selim MA, Mahalingam M, Flaherty KT, Hoang MP. Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome. J Am Acad Dermatol. 2016 Sep; 75(3):595-602. PMID: 27543214.
    View in: PubMed
  28. Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong L, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. Clin Cancer Res. 2016 Dec 15; 22(24):6088-6098. PMID: 27515299.
    View in: PubMed
  29. Shen CH, Kim SH, Trousil S, Frederick DT, Piris A, Yuan P, Cai L, Gu L, Li M, Lee JH, Mitra D, Fisher DE, Sullivan RJ, Flaherty KT, Zheng B. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med. 2016 Sep; 22(9):1056-61. PMID: 27500726; PMCID: PMC5014622 [Available on 03/01/17].
  30. Weber ML, Liang MC, Flaherty KT, Heier JS. Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer. JAMA Ophthalmol. 2016 Aug 01; 134(8):855-62. PMID: 27309887.
    View in: PubMed
  31. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Sep 08; 537(7619):254. PMID: 27383789.
    View in: PubMed
  32. Eliades P, Miller DM, Miao B, Kumar R, Taylor M, Buch S, Srinivasa SP, Flaherty KT, Tsao H. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biol Ther. 2016 Jul 02; 17(7):778-84. PMID: 26810603; PMCID: PMC4970529 [Available on 01/25/17].
  33. Niessner H, Schmitz J, Tabatabai G, Schmid AM, Calaminus C, Sinnberg T, Weide B, Eigentler TK, Garbe C, Schittek B, Quintanilla-Fend L, Bender B, Mai M, Praetorius C, Beissert S, Schackert G, Muders MH, Meinhardt M, Baretton GB, Dummer R, Flaherty K, Pichler BJ, Kulms D, Westphal D, Meier F. PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo. Clin Cancer Res. 2016 Dec 01; 22(23):5818-5828. PMID: 27307593.
    View in: PubMed
  34. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov. 2016 Jul; 6(7):740-53. PMID: 27217383.
    View in: PubMed
  35. Jonas O, Oudin MJ, Kosciuk T, Whitman M, Gertler FB, Cima MJ, Flaherty KT, Langer R. Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities. Clin Cancer Res. 2016 Dec 15; 22(24):6031-6038. PMID: 27091406.
    View in: PubMed
  36. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 Jul; 29(4):404-16. PMID: 27087480.
    View in: PubMed
  37. Tateishi K, Iafrate AJ, Ho Q, Curry WT, Batchelor TT, Flaherty KT, Onozato ML, Lelic N, Sundaram S, Cahill DP, Chi AS, Wakimoto H. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res. 2016 Sep 01; 22(17):4452-65. PMID: 27076630; PMCID: PMC5010492 [Available on 03/01/17].
  38. Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin JR, Cohen O, Shah P, Lu D, Genshaft AS, Hughes TK, Ziegler CG, Kazer SW, Gaillard A, Kolb KE, Villani AC, Johannessen CM, Andreev AY, Van Allen EM, Bertagnolli M, Sorger PK, Sullivan RJ, Flaherty KT, Frederick DT, Jané-Valbuena J, Yoon CH, Rozenblatt-Rosen O, Shalek AK, Regev A, Garraway LA. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016 Apr 08; 352(6282):189-96. PMID: 27124452; PMCID: PMC4944528.
  39. Kato S, Lippman SM, Flaherty KT, Kurzrock R. The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst. 2016 Aug; 108(8). PMID: 27059373; PMCID: PMC5017937.
  40. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Apr 14; 532(7598):250-4. PMID: 27042933; PMCID: PMC4833579 [Available on 10/04/16].
  41. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest. 2016 May 02; 126(5):1834-56. PMID: 27043285; PMCID: PMC4855947.
  42. Miller MA, Oudin MJ, Sullivan RJ, Wang SJ, Meyer AS, Im H, Frederick DT, Tadros J, Griffith LG, Lee H, Weissleder R, Flaherty KT, Gertler FB, Lauffenburger DA. Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. Cancer Discov. 2016 Apr; 6(4):382-99. PMID: 26984351.
    View in: PubMed
  43. Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell. 2016 Mar 14; 29(3):270-84. PMID: 26977879; PMCID: PMC4796027.
  44. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 May 14; 387(10032):2008-16. PMID: 26969090; PMCID: PMC4878938 [Available on 05/14/17].
  45. Roh MR, Gupta S, Park KH, Chung KY, Lauss M, Flaherty KT, Jönsson G, Rha SY, Tsao H. Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. J Invest Dermatol. 2016 May; 136(5):1002-11. PMID: 26854490.
    View in: PubMed
  46. Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, Flaherty KT, Nota S, Giannarelli D, Simeone E, Anniciello AM, Palmieri G, Pepe S, Botti G, Ascierto PA, Ferrone CR, Ferrone S. Antitumor Activity of BRAF Inhibitor and IFNa Combination in BRAF-Mutant Melanoma. J Natl Cancer Inst. 2016 Jul; 108(7). PMID: 26851802; PMCID: PMC4948304 [Available on 07/01/17].
  47. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016 Mar; 5(3):e1136044. PMID: 27141370.
    View in: PubMed
  48. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016 Mar 10; 34(8):871-8. PMID: 26811525.
    View in: PubMed
  49. Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. Eur J Cancer. 2016 Jan; 53:125-34. PMID: 26707829.
    View in: PubMed
  50. Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JJ, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MVA, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 2015 Dec 14; 28(6):773-784. PMID: 26678339; PMCID: PMC4684594 [Available on 12/14/16].
  51. Fofaria NM, Frederick DT, Sullivan RJ, Flaherty KT, Srivastava SK. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Oncotarget. 2015 Dec 01; 6(38):40535-56. PMID: 26497853; PMCID: PMC4747351.
  52. Lo JA, Fisher DE, Flaherty KT. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. JAMA Oncol. 2015 Dec; 1(9):1340-1. PMID: 26270186.
    View in: PubMed
  53. Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015 Dec; 15(12):747-56. PMID: 26536825; PMCID: PMC4970460.
  54. Flaherty KT. New drugs in development for melanoma. Clin Adv Hematol Oncol. 2015 Nov; 13(11):717-9. PMID: 27058694.
    View in: PubMed
  55. Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber DA, Flaherty KT, Wargo JA, Ramaswamy S, Benes CH, Fisher DE. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One. 2015; 10(10):e0140310. PMID: 26461489; PMCID: PMC4604168.
  56. Betof AS, Rubin KM, Blackmon SM, Flaherty K, Lawrence DP, Sullivan RJ. Palliative care and hospice use among melanoma patients treated with immunotherapy. J Clin Oncol. 2015 Oct 10; 33(29_suppl):116. PMID: 28148099.
    View in: PubMed
  57. Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, Haney P, O'Hagan A, Carver J, Goodman V, Legos J, Martin AM. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clin Cancer Res. 2016 Feb 01; 22(3):567-74. PMID: 26446943.
    View in: PubMed
  58. Grob JJ, Long GV, Schadendorf D, Flaherty K. Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. Lancet Oncol. 2015 Oct; 16(13):e522-6. PMID: 26433825.
    View in: PubMed
  59. Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015 Oct; 16(13):1389-98. PMID: 26433819.
    View in: PubMed
  60. Sullivan RJ, Flaherty KT. Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma. Nat Rev Clin Oncol. 2015 Nov; 12(11):625-6. PMID: 26416151.
    View in: PubMed
  61. Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W, Cozzio A, Dummer R, Mihm MC, Flaherty KT, Frank MH, Murphy GF, Sharpe AH, Kupper TS, Schatton T. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell. 2015 Sep 10; 162(6):1242-56. PMID: 26359984; PMCID: PMC4700833.
  62. Cao J, Dai X, Wan L, Wang H, Zhang J, Goff PS, Sviderskaya EV, Xuan Z, Xu Z, Xu X, Hinds P, Flaherty KT, Faller DV, Goding CR, Wang Y, Wei W, Cui R. The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth. Sci Signal. 2015 Sep 01; 8(392):ra87. PMID: 26329581.
    View in: PubMed
  63. Wilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst B, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res. 2016 Jan 15; 22(2):374-82. PMID: 26307133; PMCID: PMC4821426 [Available on 01/15/17].
  64. Fedorenko IV, Wargo JA, Flaherty KT, Messina JL, Smalley KSM. BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. J Invest Dermatol. 2015 Dec; 135(12):3115-3124. PMID: 26302068; PMCID: PMC4648653.
  65. Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clin Cancer Res. 2015 Dec 01; 21(23):5215-21. PMID: 26202952; PMCID: PMC4668213 [Available on 12/01/16].
  66. Mochel MC, Hammond MR, Frederick DT, Alora-Palli MB, Piris A, Flaherty KT, Hoang MP. Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients. J Am Acad Dermatol. 2015 Sep; 73(3):491-9.e2. PMID: 26190239.
    View in: PubMed
  67. Verduzco D, Flaherty KT, Smalley KS. Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma. Exp Dermatol. 2015 Sep; 24(9):657-8. PMID: 26010519; PMCID: PMC4537671 [Available on 09/01/16].
  68. Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher M, Chen H, Sehgal C, O'Dwyer PJ. Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. Oncologist. 2015 Aug; 20(8):952-9. PMID: 26084808; PMCID: PMC4524755.
  69. Flaherty KT, Manola JB, Pins M, McDermott DF, Atkins MB, Dutcher JJ, George DJ, Margolin KA, DiPaola RS. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). J Clin Oncol. 2015 Jul 20; 33(21):2384-91. PMID: 26077237; PMCID: PMC4500832 [Available on 07/20/16].
  70. Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2016 Mar 10; 35(10):1225-35. PMID: 26073081; PMCID: PMC4679729.
  71. Villaruz LC, Huang G, Romkes M, Kirkwood JM, Buch SC, Nukui T, Flaherty KT, Lee SJ, Wilson MA, Nathanson KL, Benos PV, Tawbi HA. MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clin Epigenetics. 2015; 7:58. PMID: 26052356; PMCID: PMC4457092.
  72. Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M. Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. Nat Med. 2015 Jul; 21(7):741-50. PMID: 26030178; PMCID: PMC4968631.
  73. Sullivan RJ, Flaherty KT. New strategies in melanoma: entering the era of combinatorial therapy. Clin Cancer Res. 2015 Jun 01; 21(11):2424-35. PMID: 26034218.
    View in: PubMed
  74. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015 Aug 01; 386(9992):444-51. PMID: 26037941.
    View in: PubMed
  75. Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, Wargo JA, Dummer R, Flaherty KT, Ronai ZA. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Rep. 2015 Jun 09; 11(9):1458-73. PMID: 26027934.
    View in: PubMed
  76. Sullivan RJ, Ibrahim N, Lawrence DP, Aldridge J, Giobbie-Hurder A, Hodi FS, Flaherty KT, Conley C, Mier JW, Atkins MB, McDermott DF. A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. Oncologist. 2015 Jun; 20(6):617-8. PMID: 25986244; PMCID: PMC4571786.
  77. Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. Eur J Cancer. 2015 Jul; 51(11):1435-43. PMID: 25980594.
    View in: PubMed
  78. Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS. Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res. 2015 Sep 15; 21(18):4048-54. PMID: 25967143; PMCID: PMC4573791.
  79. Sullivan RJ, Flaherty KT. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. Clin Cancer Res. 2015 Jul 01; 21(13):2892-7. PMID: 25931451.
    View in: PubMed
  80. Wattson DA, Sullivan RJ, Niemierko A, Merritt RM, Lawrence DP, Oh KS, Flaherty KT, Shih HA. Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. J Neurooncol. 2015 May; 123(1):75-84. PMID: 25864098.
    View in: PubMed
  81. Ji Z, Erin Chen Y, Kumar R, Taylor M, Jenny Njauw CN, Miao B, Frederick DT, Wargo JA, Flaherty KT, Jönsson G, Tsao H. MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol. 2015 Jul; 135(7):1863-1872. PMID: 25789707; PMCID: PMC4466007.
  82. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, Long GV. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015 May; 51(7):833-40. PMID: 25794603.
    View in: PubMed
  83. Flaherty KT. Effectively targeting CRAF: rational serendipity targeting SRC? Pigment Cell Melanoma Res. 2015 May; 28(3):242-3. PMID: 25677495.
    View in: PubMed
  84. Jones PS, Cahill DP, Brastianos PK, Flaherty KT, Curry WT. Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series. Neurosurg Focus. 2015 Mar; 38(3):E5. PMID: 25727227.
    View in: PubMed
  85. Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, Chin L. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr; 125(4):1459-70. PMID: 25705882; PMCID: PMC4396463.
  86. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6. PMID: 25665005; PMCID: PMC4930244.
  87. Ribas A, Flaherty KT. Gauging the Long-Term Benefits of Ipilimumab in Melanoma. J Clin Oncol. 2015 Jun 10; 33(17):1865-6. PMID: 25667273.
    View in: PubMed
  88. Flaherty KT. When are signal transduction targeted therapies acting as immunotherapy? Cancer Biol Ther. 2015; 16(5):645-7. PMID: 25807058; PMCID: PMC4622753.
  89. Flaherty KT, Wargo JA, Bivona TG. YAP in MAPK pathway targeted therapy resistance. Cell Cycle. 2015; 14(12):1765-6. PMID: 26036142; PMCID: PMC4612653.
  90. Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol. 2015 Jan; 16(1):15-7. PMID: 25638540.
    View in: PubMed
  91. Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W, Becker KG, Kossenkov AV, Frederick DT, Flaherty KT, Xu X, Herlyn M, Murphy ME, Weeraratna AT. Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell Melanoma Res. 2015 Mar; 28(2):184-95. PMID: 25407936; PMCID: PMC4333017.
  92. Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar; 5(3):264-73. PMID: 25542447; PMCID: PMC4355213.
  93. Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov. 2015 Mar; 5(3):274-87. PMID: 25542448; PMCID: PMC4355085.
  94. Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014 Dec 23; 7(357):ra121. PMID: 25538079; PMCID: PMC4353587.
  95. Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann Oncol. 2015 Feb; 26(2):415-21. PMID: 25411413.
    View in: PubMed
  96. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015 Jan 01; 372(1):30-9. PMID: 25399551.
    View in: PubMed
  97. Wargo JA, Cooper ZA, Flaherty KT. Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov. 2014 Dec; 4(12):1377-86. PMID: 25395294; PMCID: PMC4258160.
  98. Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ. Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther. 2014 Dec; 13(12):3210-8. PMID: 25319388; PMCID: PMC4258469 [Available on 12/01/15].
  99. Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014 Nov 20; 32(33):3697-704. PMID: 25287827; PMCID: PMC4226803 [Available on 11/20/15].
  100. Smith MP, Sanchez-Laorden B, O'Brien K, Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick DT, Cooper ZA, Wargo JA, Marais R, Wellbrock C. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFa. Cancer Discov. 2014 Oct; 4(10):1214-1229. PMID: 25256614; PMCID: PMC4184867.
  101. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014 Nov 13; 371(20):1877-88. PMID: 25265492.
    View in: PubMed
  102. Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2015 Mar; 28(2):135-47. PMID: 25113308; PMCID: PMC4326637 [Available on 03/01/16].
  103. Romano D, Matallanas D, Frederick DT, Flaherty KT, Kolch W. One Hippo and many masters: differential regulation of the Hippo pathway in cancer. Biochem Soc Trans. 2014 Aug; 42(4):816-21. PMID: 25109963.
    View in: PubMed
  104. Haq R, Flaherty K. The melanoma metastasis X-factor. Pigment Cell Melanoma Res. 2014 Sep; 27(5):698. PMID: 24953382.
    View in: PubMed
  105. Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286. PMID: 24983357; PMCID: PMC4077767.
  106. Miller DM, Flaherty KT, Tsao H. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Semin Cutan Med Surg. 2014 Jun; 33(2):60-7. PMID: 25085663.
    View in: PubMed
  107. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54. PMID: 24903021; PMCID: PMC4097121.
  108. Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014 Jul; 4(7):816-27. PMID: 24771846; PMCID: PMC4154497.
  109. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014 Jul; 2(7):632-42. PMID: 24838938; PMCID: PMC4306338.
  110. Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA. Isolation and molecular characterization of circulating melanoma cells. Cell Rep. 2014 May 08; 7(3):645-53. PMID: 24746818; PMCID: PMC4079008.
  111. Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma. Oncotarget. 2014 Apr 15; 5(7):1701-52. PMID: 24743024; PMCID: PMC4039128.
  112. Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR. PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014 Apr 15; 5(7):1926-41. PMID: 24732172; PMCID: PMC4039118.
  113. Wilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 2014 Jun 15; 20(12):3328-37. PMID: 24714776; PMCID: PMC4058354.
  114. Padmanabhan RK, Somasundar VH, Griffith SD, Zhu J, Samoyedny D, Tan KS, Hu J, Liao X, Carin L, Yoon SS, Flaherty KT, Dipaola RS, Heitjan DF, Lal P, Feldman MD, Roysam B, Lee WM. An active learning approach for rapid characterization of endothelial cells in human tumors. PLoS One. 2014; 9(3):e90495. PMID: 24603893; PMCID: PMC3946171.
  115. Park JJ, Hawryluk EB, Tahan SR, Flaherty K, Kim CC. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol. 2014 Mar; 150(3):307-11. PMID: 24352115.
    View in: PubMed
  116. Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, Menzies AM, Atkins MB, Long GV, Sullivan RJ. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014 Jun 01; 120(11):1695-701. PMID: 24577748.
    View in: PubMed
  117. Miller DM, Flaherty KT, Tsao H. Commentary: Molecular testing in melanoma. J Am Acad Dermatol. 2014 May; 70(5):863-70. PMID: 24534656.
    View in: PubMed
  118. Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, Coit DG, Eggermont AM, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, Ross MI, Byrd DR, Cochran AJ, Mihm MC, Morton DL, Atkins MB, Flaherty KT, Sondak VK. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81. PMID: 24531700; PMCID: PMC4121329.
  119. Miller DM, Flaherty KT. Cyclin-dependent kinases as therapeutic targets in melanoma. Pigment Cell Melanoma Res. 2014 May; 27(3):351-65. PMID: 24405945.
    View in: PubMed
  120. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014 Mar; 15(3):323-32. PMID: 24508103; PMCID: PMC4382632.
  121. Griewank KG, Scolyer RA, Thompson JF, Flaherty KT, Schadendorf D, Murali R. Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst. 2014 Feb; 106(2):djt435. PMID: 24511108.
    View in: PubMed
  122. Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM, Hauschild A, Kefford R, Kirkwood JM, Long GV, Lorigan P, Mackensen A, McArthur G, O'Day S, Patel PM, Robert C, Schadendorf D. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol. 2014 Mar; 15(3):297-304. PMID: 24485879; PMCID: PMC4443445.
  123. Flaherty L, Hamid O, Linette G, Schuchter L, Hallmeyer S, Gonzalez R, Cowey CL, Pavlick A, Kudrik F, Curti B, Lawson D, Chapman PB, Margolin K, Ribas A, McDermott D, Flaherty K, Cranmer L, Hodi FS, Day BM, Linke R, Hainsworth J. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J. 2014 Jan-Feb; 20(1):18-24. PMID: 24445759; PMCID: PMC4705837.
  124. Sullivan RJ, Flaherty KT. Major therapeutic developments and current challenges in advanced melanoma. Br J Dermatol. 2014 Jan; 170(1):36-44. PMID: 24443912.
    View in: PubMed
  125. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan; 4(1):61-8. PMID: 24265154; PMCID: PMC3947296.
  126. Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013 Dec 05; 504(7478):138-42. PMID: 24185007; PMCID: PMC4098832.
  127. O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013 Dec; 3(12):1378-93. PMID: 24104062; PMCID: PMC3918498.
  128. Sullivan RJ, Lorusso PM, Flaherty KT. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res. 2013 Oct 01; 19(19):5283-91. PMID: 24089441; PMCID: PMC4100326.
  129. Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology. 2013 Oct 01; 2(10):e26615. PMID: 24251082.
    View in: PubMed
  130. Ciunci CA, Perini RF, Avadhani AN, Kang HC, Sun W, Redlinger M, Harlacker K, Flaherty KT, Giantonio BJ, Rosen MA, Divgi CR, Song HK, Englander S, Troxel A, Schnall M, O'Dwyer PJ. Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer. 2014 Jan 01; 120(1):77-85. PMID: 24108668.
    View in: PubMed
  131. Juric D, Isakoff SJ, Borger DR, Dias-Santagata D, Higgins MJ, Iafrate AJ, Flaherty K, Moy B, Ellisen LW. Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review. J Clin Oncol. 2013 Sep 10; 31(26_suppl):145. PMID: 28136532.
    View in: PubMed
  132. Fridlyand J, Simon RM, Walrath JC, Roach N, Buller R, Schenkein DP, Flaherty KT, Allen JD, Sigal EV, Scher HI. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov. 2013 10; 12(10):743-55. PMID: 24008432.
    View in: PubMed
  133. Jilaveanu LB, Zhao F, Zito CR, Kirkwood JM, Nathanson KL, D'Andrea K, Wilson M, Rimm DL, Flaherty KT, Lee SJ, Kluger HM. Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One. 2013; 8(8):e69748. PMID: 23936348; PMCID: PMC3735539.
  134. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Oct 15; 119(20):3687-95. PMID: 23913718; PMCID: PMC3986037.
  135. Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med. 2013 Jul 31; 5(196):196ra98. PMID: 23903755; PMCID: PMC3867020.
  136. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, Ding S, Cochran AJ, Eggermont AM, Flaherty KT, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VK. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov; 20(12):3961-8. PMID: 23838920; PMCID: PMC4121330.
  137. Ji Z, Kumar R, Taylor M, Rajadurai A, Marzuka-Alcalá A, Chen YE, Njauw CN, Flaherty K, Jönsson G, Tsao H. Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res. 2013 Aug 15; 19(16):4383-91. PMID: 23812671; PMCID: PMC3777641.
  138. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90. PMID: 23775962; PMCID: PMC4878082.
  139. Salama AK, Flaherty KT. BRAF in melanoma: current strategies and future directions. Clin Cancer Res. 2013 Aug 15; 19(16):4326-34. PMID: 23770823.
    View in: PubMed
  140. Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD. Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013 Jun; 18(6):726-32. PMID: 23716015; PMCID: PMC4063400.
  141. Bennett A, Bukowski RM, Flaherty K, Muir JC, Turner CD, Donaldson S. The Cost of Hope: a candid roundtable discussion. J Natl Compr Canc Netw. 2013 May; 11(5 Suppl):633-5. PMID: 23704231.
    View in: PubMed
  142. Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kauffman M, Cusack JC. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther. 2013 Jul; 12(7):1171-9. PMID: 23615632.
    View in: PubMed
  143. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74. PMID: 23569304.
    View in: PubMed
  144. Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M. Meeting report: The future of preclinical mouse models in melanoma treatment is now. Pigment Cell Melanoma Res. 2013 Jul; 26(4):E8-E14. PMID: 23531109; PMCID: PMC4109982.
  145. Desai BM, Villanueva J, Nguyen TT, Lioni M, Xiao M, Kong J, Krepler C, Vultur A, Flaherty KT, Nathanson KL, Smalley KS, Herlyn M. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One. 2013; 8(3):e59588. PMID: 23527225; PMCID: PMC3601112.
  146. Motiwala S, O'Dwyer PJ, Flaherty KT, Keefe SM. Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors. J Clin Oncol. 2013 Feb 20; 31(6_suppl):384. PMID: 28136886.
    View in: PubMed
  147. Manola J, Pins M, Flaherty KT, Atkins MB, Dutcher JP, George DJ, Margolin KA, DiPaola RS. The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):345. PMID: 28137008.
    View in: PubMed
  148. Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, Flaherty K, Sinnberg T, Beck D, Leiter U, Mauch C, Roesch A, Weide B, Eigentler T, Schadendorf D, Garbe C, Kulms D, Quintanilla-Martinez L, Meier F. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med. 2013 Feb; 2(1):76-85. PMID: 24133630; PMCID: PMC3797558.
  149. Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen S, Stork B, Wesselborg S, Schaller M, Biedermann T, Bauer J, Lasithiotakis K, Weide B, Eberle J, Schittek B, Schadendorf D, Garbe C, Kulms D, Meier F. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal. 2013 Jan 29; 6(260):ra7. PMID: 23362240; PMCID: PMC3698985.
  150. Hollebecque A, Postel-Vinay S, Verweij J, Demetri GD, Flaherty K, Bedard P, Soria JC. Modifying phase I methodology to facilitate enrolment of molecularly selected patients. Eur J Cancer. 2013 May; 49(7):1515-20. PMID: 23333057.
    View in: PubMed
  151. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31. PMID: 23307859; PMCID: PMC3752683.
  152. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer. 2013 Apr; 49(6):1297-304. PMID: 23290787.
    View in: PubMed
  153. Kang HC, Tan KS, Keefe SM, Heitjan DF, Siegelman ES, Flaherty KT, O'Dwyer PJ, Rosen MA. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. AJR Am J Roentgenol. 2013 Jan; 200(1):120-6. PMID: 23255750.
    View in: PubMed
  154. Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013 Jan 20; 31(3):373-9. PMID: 23248256; PMCID: PMC4878104.
  155. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin L. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012 Dec 6; 18(12):1857. PMID: 23223074.
    View in: PubMed
  156. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013 Jan 10; 31(2):181-6. PMID: 23213094; PMCID: PMC3532390.
  157. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403. PMID: 23204132; PMCID: PMC4120472.
  158. Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 2013 Jan 15; 19(2):480-90. PMID: 23186780.
    View in: PubMed
  159. Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013 Mar; 3(3):338-49. PMID: 23171796; PMCID: PMC3595355.
  160. Belden S, Flaherty KT. MEK and RAF inhibitors for BRAF-mutated cancers. Expert Rev Mol Med. 2012 Oct 12; 14:e17. PMID: 23058743.
    View in: PubMed
  161. Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol. 2013 Feb; 24(2):530-7. PMID: 23035153.
    View in: PubMed
  162. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 11 01; 367(18):1694-703. PMID: 23020132; PMCID: PMC3549295.
  163. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin L. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012 Oct; 18(10):1503-10. PMID: 22983396; PMCID: PMC3777533.
  164. Sullivan RJ, Flaherty K. MAP kinase signaling and inhibition in melanoma. Oncogene. 2013 May 09; 32(19):2373-9. PMID: 22945644.
    View in: PubMed
  165. Flaherty KT. Throwing the kitchen sink at melanoma drug development. Pigment Cell Melanoma Res. 2012 Sep; 25(5):543-4. PMID: 22812391.
    View in: PubMed
  166. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Jul 26; 487(7408):500-4. PMID: 22763439; PMCID: PMC3711467.
  167. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):773-81. PMID: 22805291.
    View in: PubMed
  168. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9. PMID: 22805292; PMCID: PMC4109286.
  169. Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83. PMID: 22551296; PMCID: PMC3390271.
  170. Flaherty KT, Hersey P, Nathan PD, Garbe C, Milhem MM, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Casey M, Sherman LJ, Crist WA, Wu FS, Patel K, Schadendorf D. METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). J Clin Oncol. 2012 Jun 20; 30(18_suppl):LBA8509. PMID: 28140819.
    View in: PubMed
  171. Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer. 2012 Dec 15; 118(24):6055-62. PMID: 22674198; PMCID: PMC3934426.
  172. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12; 367(2):107-14. PMID: 22663011.
    View in: PubMed
  173. Flaherty KT. Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. Clin Exp Metastasis. 2012 Oct; 29(7):841-6. PMID: 22661223.
    View in: PubMed
  174. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012 Apr 05; 12(5):349-61. PMID: 22475929.
    View in: PubMed
  175. McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, Sosman JA, Lee RJ, Nolop K, Flaherty KT, Callahan J, Hicks RJ. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol. 2012 May 10; 30(14):1628-34. PMID: 22454415.
    View in: PubMed
  176. Alloo A, Garibyan L, LeBoeuf N, Lin G, Werchniak A, Hodi FS, Flaherty KT, Lawrence DP, Lin JY. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol. 2012 Mar; 148(3):363-6. PMID: 22431777.
    View in: PubMed
  177. Dummer R, Flaherty KT. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol. 2012 Mar; 24(2):150-4. PMID: 22316627.
    View in: PubMed
  178. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23; 366(8):707-14. PMID: 22356324; PMCID: PMC3724515.
  179. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19; 366(3):207-15. PMID: 22256804; PMCID: PMC3724537.
  180. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012 Mar; 2(3):227-35. PMID: 22448344; PMCID: PMC3308191.
  181. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: new insights and new therapies. J Invest Dermatol. 2012 Mar; 132(3 Pt 2):854-63. PMID: 22217739; PMCID: PMC3759013.
  182. Alcalá AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res. 2012 Jan 01; 18(1):33-9. PMID: 22215904.
    View in: PubMed
  183. Flaherty KT, Sosman JA, Atkins MB. New options and new questions: how to select and sequence therapies for patients with metastatic melanoma. Am Soc Clin Oncol Educ Book. 2012; 524-30. PMID: 24451790.
    View in: PubMed
  184. Si L, Xu X, Kong Y, Flaherty KT, Chi Z, Cui C, Sheng X, Li S, Dai J, Yu W, Guo J. Major response to everolimus in melanoma with acquired imatinib resistance. J Clin Oncol. 2012 Feb 01; 30(4):e37-40. PMID: 22162580.
    View in: PubMed
  185. Smalley KS, Aplin AE, Flaherty KT, Hoeller C, Bosserhoff AK, Haass NK, Bosenberg M, Ribas A, Barnhill R, Kudchadkar R, Messina JL. Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res. 2012 Jan; 25(1):E1-11. PMID: 22117673.
    View in: PubMed
  186. Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK, Kirkwood JM. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):336-41. PMID: 22142824; PMCID: PMC3422891.
  187. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23; 480(7377):387-90. PMID: 22113612; PMCID: PMC3266695.
  188. Sullivan RJ, Flaherty KT. BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. J Skin Cancer. 2011; 2011:423239. PMID: 22175026; PMCID: PMC3235817.
  189. Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, Shaik MN, Wilner KD, O'Dwyer PJ, Schwartz GK. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012 Jan 15; 18(2):568-76. PMID: 22090362.
    View in: PubMed
  190. Flaherty KT. BRAF inhibitors and melanoma. Cancer J. 2011 Nov-Dec; 17(6):505-11. PMID: 22157295.
    View in: PubMed
  191. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov. 2011 Oct 31; 10(11):811-2. PMID: 22037033.
    View in: PubMed
  192. Flaherty KT. Targeting metastatic melanoma. Annu Rev Med. 2012; 63:171-83. PMID: 22034865.
    View in: PubMed
  193. Ji Z, Njauw CN, Taylor M, Neel V, Flaherty KT, Tsao H. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol. 2012 Feb; 132(2):356-64. PMID: 21993556.
    View in: PubMed
  194. Ji Z, Flaherty KT, Tsao H. Targeting the RAS pathway in melanoma. Trends Mol Med. 2012 Jan; 18(1):27-35. PMID: 21962474; PMCID: PMC3759017.
  195. Dicker DT, Kahn N, Flaherty KT, Lerner J, El-Deiry WS. Hyperspectral imaging: a non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor. Cancer Biol Ther. 2011 Aug 15; 12(4):326-34. PMID: 21768778.
    View in: PubMed
  196. Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, Chi Z, Li S, Mao L, Guo J. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer. 2012 Jan; 48(1):94-100. PMID: 21788131.
    View in: PubMed
  197. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3. PMID: 21768451; PMCID: PMC4836609.
  198. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011 Jul 20; 29(21):2904-9. PMID: 21690468.
    View in: PubMed
  199. Infante JR, Falchook GS, Lawrence DP, Weber JS, Kefford RF, Bendell JC, Kurzrock R, Shapiro G, Kudchadkar RR, Long GV, Burris HA, Kim KB, Clements A, Peng S, Yi B, Allred AJ, Ouellet D, Patel K, Lebowitz PF, Flaherty KT. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol. 2011 Jun 20; 29(18_suppl):CRA8503. PMID: 27937145.
    View in: PubMed
  200. Chapman PB, Hauschild A, Robert C, Larkin JM, Haanen JB, Ribas A, Hogg D, O'Day S, Ascierto PA, Testori A, Lorigan P, Dummer R, Sosman JA, Garbe C, Lee RJ, Nolop KB, Nelson B, Hou J, Flaherty KT, McArthur GA. Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. J Clin Oncol. 2011 Jun 20; 29(18_suppl):LBA4. PMID: 27937164.
    View in: PubMed
  201. Flaherty KT, Fisher DE. New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. Clin Cancer Res. 2011 Aug 01; 17(15):4922-8. PMID: 21670085.
    View in: PubMed
  202. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30; 364(26):2507-16. PMID: 21639808; PMCID: PMC3549296.
  203. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011 05 24; 8(7):426-33. PMID: 21606968.
    View in: PubMed
  204. Chapman PB, Hauschild A, Robert C, Larkin JM, Haanen JB, Ribas A, Hogg D, O'Day S, Ascierto PA, Testori A, Lorigan P, Dummer R, Sosman JA, Garbe C, Lee RJ, Nolop KB, Nelson B, Hou J, Flaherty KT, McArthur GA. Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. J Clin Oncol. 2011 May 20; 29(15_suppl):LBA4. PMID: 28024023.
    View in: PubMed
  205. Infante JR, Falchook GS, Lawrence DP, Weber JS, Kefford RF, Bendell JC, Kurzrock R, Shapiro G, Kudchadkar RR, Long GV, Burris HA, Kim KB, Clements A, Peng S, Yi B, Allred AJ, Ouellet D, Patel K, Lebowitz PF, Flaherty KT. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol. 2011 May 20; 29(15_suppl):CRA8503. PMID: 28021992.
    View in: PubMed
  206. Martin CA, Perini RF, Avadhani AN, Redlinger M, Harlacker K, Flaherty KT, Rosen MA, Divgi CR, O'Dwyer PJ. Imaging with [18f]-fluorodeoxyglucose positron emission tomography (FDG-PET) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) as markers of drug effect in a phase I dose-escalation study of combined RAD 001 and cetuximab. J Clin Oncol. 2011 May 20; 29(15_suppl):3048. PMID: 28022635.
    View in: PubMed
  207. Kim KB, Flaherty KT, Chapman PB, Sosman JA, Ribas A, McArthur GA, Amaravadi RK, Lee RJ, Nolop KB, Puzanov I. Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). J Clin Oncol. 2011 May 20; 29(15_suppl):8519. PMID: 28021137.
    View in: PubMed
  208. Sharfman WH, Hodi FS, Lawrence DP, Flaherty KT, Amaravadi RK, Kim KB, Dummer R, Gobbi S, Puzanov I, Sosman JA, Dohoney K, Lam LP, Kakar S, Tang Z, Krieter O, Atkins MB. Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. J Clin Oncol. 2011 May 20; 29(15_suppl):8508. PMID: 28021164.
    View in: PubMed
  209. McArthur GA, Ribas A, Chapman PB, Flaherty KT, Kim KB, Puzanov I, Nathanson KL, Lee RJ, Koehler A, Spleiss O, Bollag G, Wu W, Trunzer K, Sosman JA. Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts). J Clin Oncol. 2011 May 20; 29(15_suppl):8502. PMID: 28021161.
    View in: PubMed
  210. Lacouture ME, Chapman PB, Ribas A, Sosman JA, McArthur GA, Flaherty KT, Kim KB, Puzanov I, Nolop KB, Joe AK, Spleiss O, Koehler A, Wu W, Robert C, Hauschild A, Schadendorf D, Troy JL, Duvic M, Trunzer K. Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):8520. PMID: 28021108.
    View in: PubMed
  211. Meier FE, Beck D, Niessner H, Flaherty KT, Iovanna J, Kulms D, Schadendorf D, Garbe C. Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genes. J Clin Oncol. 2011 May 20; 29(15_suppl):8518. PMID: 28021138.
    View in: PubMed
  212. Ribas A, Kim KB, Schuchter LM, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Flaherty KT, Moschos SJ, Lawrence DP, Hersey P, Kefford RF, Chmielowski B, Puzanov I, Li J, Nolop KB, Lee RJ, Joe AK, Sosman JA. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol. 2011 May 20; 29(15_suppl):8509. PMID: 28021163.
    View in: PubMed
  213. Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC, Morton DL, Sondak VK. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011 Jun 01; 29(16):2199-205. PMID: 21519009; PMCID: PMC3107741.
  214. Flaherty KT. Next generation therapies change the landscape in melanoma. F1000 Med Rep. 2011; 3:8. PMID: 21654923; PMCID: PMC3096880.
  215. Vidwans SJ, Flaherty KT, Fisher DE, Tenenbaum JM, Travers MD, Shrager J. A melanoma molecular disease model. PLoS One. 2011 Mar 30; 6(3):e18257. PMID: 21479172; PMCID: PMC3068163.
  216. Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, Lee PP, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011 Mar 26; 9:32. PMID: 21439082; PMCID: PMC3078100.
  217. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov; 68(5):1111-8. PMID: 21350850.
    View in: PubMed
  218. Flaherty KT. Is it good or bad to find a BRAF mutation? J Clin Oncol. 2011 Apr 01; 29(10):1229-30. PMID: 21343552.
    View in: PubMed
  219. Puzanov I, Burnett P, Flaherty KT. Biological challenges of BRAF inhibitor therapy. Mol Oncol. 2011 Apr; 5(2):116-23. PMID: 21393075.
    View in: PubMed
  220. Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo J. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res. 2011 Apr 01; 17(7):1684-91. PMID: 21325067.
    View in: PubMed
  221. Flaherty KT. Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress. Pigment Cell Melanoma Res. 2011 Feb; 24(1):107-9. PMID: 21232025.
    View in: PubMed
  222. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16; 468(7326):968-72. PMID: 21107320; PMCID: PMC3058384.
  223. Flaherty KT. Narrative review: BRAF opens the door for therapeutic advances in melanoma. Ann Intern Med. 2010 Nov 02; 153(9):587-91. PMID: 21041578.
    View in: PubMed
  224. Flaherty KT, McArthur G. BRAF, a target in melanoma: implications for solid tumor drug development. Cancer. 2010 Nov 01; 116(21):4902-13. PMID: 20629085.
    View in: PubMed
  225. Niessner H, Beck D, Sinnberg T, Lasithiotakis K, Maczey E, Gogel J, Venturelli S, Berger A, Mauthe M, Toulany M, Flaherty K, Schaller M, Schadendorf D, Proikas-Cezanne T, Schittek B, Garbe C, Kulms D, Meier F. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. J Invest Dermatol. 2011 Feb; 131(2):468-79. PMID: 20944654.
    View in: PubMed
  226. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010 Sep 30; 467(7315):596-9. PMID: 20823850; PMCID: PMC2948082.
  227. Puzanov I, Flaherty KT. Targeted molecular therapy in melanoma. Semin Cutan Med Surg. 2010 Sep; 29(3):196-201. PMID: 21051014.
    View in: PubMed
  228. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010 Aug 26; 363(9):809-19. PMID: 20818844; PMCID: PMC3724529.
  229. Agarwala SS, di Pietro A, Flaherty KT, Garbe C, Grob JJ, Kashani-Sabet M, Kirkwood JM, Leachman S, Messina J, O'Day S, Ribas A, Sondak V. Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res. 2010 Oct; 23(5):e1-7. PMID: 20718940.
    View in: PubMed
  230. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010 Jul 01; 70(13):5213-9. PMID: 20551059.
    View in: PubMed
  231. Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer. 2010 Jun 08; 102(12):1724-30. PMID: 20531415; PMCID: PMC2883709.
  232. Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol. 2010 May; 22(3):178-83. PMID: 20401974; PMCID: PMC3107971.
  233. Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, O'Dwyer PJ, Wilding G. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Feb; 67(2):305-14. PMID: 20386909; PMCID: PMC3050703.
  234. Flaherty KT, Puzanov I. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochem Pharmacol. 2010 Sep 01; 80(5):638-46. PMID: 20382128.
    View in: PubMed
  235. Ji Z, Flaherty KT, Tsao H. Molecular therapeutic approaches to melanoma. Mol Aspects Med. 2010 Apr; 31(2):194-204. PMID: 20176049.
    View in: PubMed
  236. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010 Apr; 11(4):373-82. PMID: 20171141.
    View in: PubMed
  237. Flaherty K. Advances in drug development. BRAF validation in melanoma. Clin Adv Hematol Oncol. 2010 Jan; 8(1):31-4. PMID: 20351680.
    View in: PubMed
  238. Flaherty KT. Where does the combination of sorafenib and interferon in renal cell carcinoma stand? Cancer. 2010 Jan 01; 116(1):4-7. PMID: 19890962.
    View in: PubMed
  239. Pacey S, Ratain MJ, Flaherty KT, Kaye SB, Cupit L, Rowinsky EK, Xia C, O'Dwyer PJ, Judson IR. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs. 2011 Jun; 29(3):481-8. PMID: 20016927.
    View in: PubMed
  240. Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K, Carberry M, Troxel AB, Letrero R, Nathanson KL, Atkins MB, O'Dwyer PJ, Flaherty KT. Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res. 2009 Dec 15; 15(24):7711-7718. PMID: 19996224.
    View in: PubMed
  241. Flaherty KT, Brose MS. Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment. Clin Cancer Res. 2009 Dec 15; 15(24):7749. PMID: 20008857.
    View in: PubMed
  242. Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol. 2010 Mar; 41(3):375-84. PMID: 20004943; PMCID: PMC2824079.
  243. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20; 27(36):6199-206. PMID: 19917835; PMCID: PMC2793035.
  244. Smalley KS, Flaherty KT. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future Oncol. 2009 Aug; 5(6):775-8. PMID: 19663727.
    View in: PubMed
  245. Flaherty KT, Smalley KS. Preclinical and clinical development of targeted therapy in melanoma: attention to schedule. Pigment Cell Melanoma Res. 2009 Oct; 22(5):529-31. PMID: 19619259.
    View in: PubMed
  246. Agarwala SS, Becker JC, Eggermont AM, Flaherty KT, Garbe C, Goldstein AM, Halpern A, Kashani-Sabet M, Hauschild A, Kirkwood JM, Leachman S, Lorigan P, McMahon M, Messina J, Ribas A, Samlowski WE, Schadendorf D, Sondak VK. Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. Pigment Cell Melanoma Res. 2009 Oct; 22(5):532-43. PMID: 19659612.
    View in: PubMed
  247. Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan DE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM, Vonderheide RH. Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res. 2009 Jul 01; 15(13):4277-87. PMID: 19549767; PMCID: PMC2896505.
  248. Fecher LA, Amaravadi RK, Schuchter LM, Flaherty KT. Drug targeting of oncogenic pathways in melanoma. Hematol Oncol Clin North Am. 2009 Jun; 23(3):599-618, x. PMID: 19464605.
    View in: PubMed
  249. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):9000. PMID: 27962338.
    View in: PubMed
  250. Brose MS, Troxel AB, Redlinger M, Harlacker K, Redlinger C, Chalian AA, Flaherty KT, Loevner LA, Mandel SJ, O'Dwyer PJ. Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients. J Clin Oncol. 2009 May 20; 27(15_suppl):6002. PMID: 27962409.
    View in: PubMed
  251. Cetnar JP, Rosen MA, Vaughn DJ, Haas NB, Troxel AB, Song H, Adluru G, Flaherty KT, O'Dwyer PJ, Amaravadi RK. Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2009 May 20; 27(15_suppl):e16055. PMID: 27962998.
    View in: PubMed
  252. Meier FE, Niessner H, Flaherty K, Schadendorf D, Sinnberg T, Schittek B, Garbe C. Effect of the farnesyl transferase inhibitor lonafarnib on sensitivity of melanoma cells to the multikinase inhibitor sorafenib and on Rheb farnesylation and mTOR signaling. J Clin Oncol. 2009 May 20; 27(15_suppl):9077. PMID: 27962181.
    View in: PubMed
  253. Thompson DS, Flaherty K, Messersmith W, Harlacker K, Nallapareddy S, Vincent C, DeMarini DJ, Cox DS, O'Neill VJ, Burris HA. A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma. J Clin Oncol. 2009 May 20; 27(15_suppl):e14584. PMID: 27963752.
    View in: PubMed
  254. Keefe S, Moyneur E, Barghout V, Flaherty KT. Dosing patterns in patients with renal cell carcinoma treated with sorafenib or sunitinib: A retrospective claims database analysis. J Clin Oncol. 2009 May 20; 27(15_suppl):5097. PMID: 27964291.
    View in: PubMed
  255. Puzanov I, Nathanson KL, Chapman PB, Xu X, Sosman JA, McArthur GA, Ribas A, Kim KB, Grippo JF, Flaherty KT. PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial. J Clin Oncol. 2009 May 20; 27(15_suppl):9021. PMID: 27962373.
    View in: PubMed
  256. Cho DC, Figlin RA, Flaherty KT, Michaelson D, Sosman JA, Ghebremichael M, Bowers ME, Mier JW, Atkins MB, McDermott DF. A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). J Clin Oncol. 2009 May 20; 27(15_suppl):5101. PMID: 27964377.
    View in: PubMed
  257. Smalley KS, Nathanson KL, Flaherty KT. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res. 2009 Apr 15; 69(8):3241-4. PMID: 19351826.
    View in: PubMed
  258. Fecher LA, Flaherty KT. Where are we with adjuvant therapy of stage III and IV melanoma in 2009? J Natl Compr Canc Netw. 2009 Mar; 7(3):295-304. PMID: 19401062.
    View in: PubMed
  259. Jilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, Rimm DL, Flaherty KT, Kluger HM. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res. 2009 Feb 01; 15(3):1076-85. PMID: 19188183; PMCID: PMC4263281.
  260. Vaughn DJ, Flaherty K, Lal P, Gallagher M, O'Dwyer P, Wilner K, Chen I, Schwartz G. Treatment of growing teratoma syndrome. N Engl J Med. 2009 Jan 22; 360(4):423-4. PMID: 19164198.
    View in: PubMed
  261. Smalley KS, Flaherty KT. Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer. 2009 Feb 10; 100(3):431-5. PMID: 19156138; PMCID: PMC2658537.
  262. Flaherty KT, Sun W. Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma? Nat Clin Pract Oncol. 2009 Feb; 6(2):64-5. PMID: 19092799.
    View in: PubMed
  263. Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J, Garbe C, Meier F. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol. 2009 Jun; 129(6):1500-15. PMID: 19078992.
    View in: PubMed
  264. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008 Dec 09; 14(6):435-46. PMID: 19061835; PMCID: PMC2621440.
  265. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene. 2009 Jan 08; 28(1):85-94. PMID: 18794803; PMCID: PMC2898184.
  266. Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008 Sep; 7(9):2876-83. PMID: 18790768; PMCID: PMC2651569.
  267. Rini BI, Flaherty K. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol. 2008 Sep-Oct; 26(5):543-9. PMID: 18774471.
    View in: PubMed
  268. Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res. 2008 Aug 01; 14(15):4836-42. PMID: 18676756.
    View in: PubMed
  269. Smalley KS, Contractor R, Nguyen TK, Xiao M, Edwards R, Muthusamy V, King AJ, Flaherty KT, Bosenberg M, Herlyn M, Nathanson KL. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res. 2008 Jul 15; 68(14):5743-52. PMID: 18632627; PMCID: PMC2615688.
  270. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008 Oct 10; 26(29):4714-9. PMID: 18541894; PMCID: PMC2653134.
  271. Fecher LA, Nathanson K, Flaherty KT, Amaravadi R, Giles L, McGettigan S, Carberry M, Elder D, Schuchter L. Phase I/II trial of imatinib and temozolomide in advanced unresectable melanoma. J Clin Oncol. 2008 May 20; 26(15_suppl):9059. PMID: 27950880.
    View in: PubMed
  272. Sosman JA, Flaherty KT, Atkins MB, McDermott DF, Rothenberg ML, Vermeulen WL, Harlacker K, Hsu A, Wright JJ, Puzanov I. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol. 2008 May 20; 26(15_suppl):5011. PMID: 27948848.
    View in: PubMed
  273. Meier F, Zielinski C, Lasithiotakis K, Sinnberg T, Flaherty KT, Schittek B, Kulms D, Garbe C. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death and abrogates invasive growth of melanoma cells. J Clin Oncol. 2008 May 20; 26(15_suppl):20033. PMID: 27947866.
    View in: PubMed
  274. Brose MS, Nellore A, Paziana K, Ransone K, Redlinger M, Flaherty KT, Mandel SJ, Troxel AB, Loevner LA, Gupta-Abramson V. A phase II study of sorafenib in metastatic thyroid carcinoma. J Clin Oncol. 2008 May 20; 26(15_suppl):6026. PMID: 27950557.
    View in: PubMed
  275. Avadhani AN, Veronese ML, Perini R, Divgi CR, Harlacker K, Sherman E, Griggs W, Flaherty KT, O'Dwyer PJ. Preliminary evaluation of response to combination of RAD001 and cetuximab using [18F]-fluorodeoxyglucose positron emission tomography (18FDG-PET). J Clin Oncol. 2008 May 20; 26(15_suppl):14525. PMID: 27950767.
    View in: PubMed
  276. Flaherty KT. The future of tyrosine kinase inhibitors: single agent or combination? Curr Oncol Rep. 2008 May; 10(3):264-70. PMID: 18765158.
    View in: PubMed
  277. Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, Maczey E, Garbe C, Meier FE. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol. 2008 Aug; 128(8):2013-23. PMID: 18323781.
    View in: PubMed
  278. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol. 2008 Mar; 20(2):183-9. PMID: 18300768.
    View in: PubMed
  279. Gimotty PA, Guerry D, Flaherty K. Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients. J Clin Oncol. 2008 Feb 01; 26(4):517-8. PMID: 18235111.
    View in: PubMed
  280. Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD, O'Dwyer PJ. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther. 2008 Apr; 7(4):496-501. PMID: 18219225.
    View in: PubMed
  281. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, Diehl JA, Smith CD, Flaherty KT, El-Deiry WS. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 2007 Oct 01; 67(19):9443-54. PMID: 17909054.
    View in: PubMed
  282. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007 Oct 10; 25(29):4536-41. PMID: 17876014.
    View in: PubMed
  283. Midgley RS, Kerr DJ, Flaherty KT, Stevenson JP, Pratap SE, Koch KM, Smith DA, Versola M, Fleming RA, Ward C, O'Dwyer PJ, Middleton MR. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol. 2007 Dec; 18(12):2025-9. PMID: 17846021.
    View in: PubMed
  284. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 2007 Jul; 12(1):66-80. PMID: 17613437.
    View in: PubMed
  285. Stein MN, Flaherty KT. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res. 2007 Jul 01; 13(13):3765-70. PMID: 17606705.
    View in: PubMed
  286. Flaherty KT. Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther. 2007 May; 7(5):617-26. PMID: 17492926.
    View in: PubMed
  287. Amaravadi RK, Flaherty KT. Targeted therapy for metastatic melanoma. Clin Adv Hematol Oncol. 2007 May; 5(5):386-94. PMID: 17673894.
    View in: PubMed
  288. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar 01; 25(7):876-83. PMID: 17327609.
    View in: PubMed
  289. Jiang W, Mikochik PJ, Ra JH, Lei H, Flaherty KT, Winkler JD, Spitz FR. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res. 2007 Feb 01; 67(3):1221-7. PMID: 17283158.
    View in: PubMed
  290. Smalley KS, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA, Flaherty KT, Herlyn M. Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer. 2007 Feb 12; 96(3):445-9. PMID: 17245336; PMCID: PMC2360037.
  291. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):667s-670s. PMID: 17255291.
    View in: PubMed
  292. Flaherty KT. Sorafenib in renal cell carcinoma. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):747s-752s. PMID: 17255304.
    View in: PubMed
  293. Smalley KS, Flaherty KT. Is ERK activation a good biomarker for estradiol and tamoxifen effects? Cancer Biol Ther. 2007 Jan; 6(1):119-20. PMID: 17264668.
    View in: PubMed
  294. Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, Herlyn M. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. 2007 Jan 01; 67(1):209-17. PMID: 17210701.
    View in: PubMed
  295. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006 Sep 04; 95(5):581-6. PMID: 16880785; PMCID: PMC2360687.
  296. Amaravadi RK, Schuchter LM, Kramer A, Barth SF, Villanueva J, Troxel AB, Tuveson DA, Nathanson KL, O'Dwyer PJ, Flaherty KT. Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):8009. PMID: 27955593.
    View in: PubMed
  297. Schiller JH, Flaherty KT, Redlinger M, Binger K, Eun J, Petrenciuc O, O'Dwyer P. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7194. PMID: 27953723.
    View in: PubMed
  298. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Gallagher M, Sullivan P, Mahaney JJ, O'Dwyer PJ, Huhn RD, Antonia SJ. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2006 Jun 20; 24(18_suppl):2507. PMID: 27954745.
    View in: PubMed
  299. Bukowski RM, Kabbinavar F, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin H, Dutcher J, Scappaticci F, McDermott D. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):4523. PMID: 27951806.
    View in: PubMed
  300. Sosman JA, Flaherty K, Atkins MB, Puzanov I, McDermott DF, Vermeulen W, Harlacker K, Hsu A, Rothenberg M. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J Clin Oncol. 2006 Jun 20; 24(18_suppl):3031. PMID: 27955036.
    View in: PubMed
  301. McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM. Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res. 2006 Jun 15; 12(12):3856-63. PMID: 16778114; PMCID: PMC1839847.
  302. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther. 2006 May; 5(5):1136-44. PMID: 16731745.
    View in: PubMed
  303. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12. PMID: 16636341.
    View in: PubMed
  304. Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L. Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2291s-2296s. PMID: 16609047.
    View in: PubMed
  305. Flaherty KT. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2366s-2370s. PMID: 16609060.
    View in: PubMed
  306. Flaherty KT, Brose MS. Her-2 targeted therapy: beyond breast cancer and trastuzumab. Curr Oncol Rep. 2006 Mar; 8(2):90-5. PMID: 16507217.
    View in: PubMed
  307. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006 Mar 20; 24(9):1363-9. PMID: 16446323.
    View in: PubMed
  308. Flaherty KT, Fuchs CS, Colditz GA, Stampfer MJ, Speizer FE, Willett WC, Curhan GC. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control. 2005 Nov; 16(9):1099-106. PMID: 16184476.
    View in: PubMed
  309. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Gore M, Desai A, Patnaik A, Xiong HQ, Schwartz B, O'Dwyer P. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2005 Jun; 23(16_suppl):4544. PMID: 27946352.
    View in: PubMed
  310. O'Dwyer PJ, Rosen M, Gallagher M, Schwartz B, Flaherty KT. Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005 Jun; 23(16_suppl):3005. PMID: 27945735.
    View in: PubMed
  311. Midgley R, Flaherty KT, Haller DG, Versola MJ, Smith DA, Koch KM, Pandite L, Kerr DJ, O'Dwyer PJ, Middleton MR. Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV). J Clin Oncol. 2005 Jun; 23(16_suppl):3086. PMID: 27945632.
    View in: PubMed
  312. Flaherty KT. VEGFR-targeted therapy. Clin Adv Hematol Oncol. 2005 May; 3(5):371-2. PMID: 16167010.
    View in: PubMed
  313. Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnall M, O'Dwyer PJ. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res. 2005 Feb 15; 11(4):1527-33. PMID: 15746056.
    View in: PubMed
  314. Veronese ML, Flaherty K, Kramer A, Konkle BA, Morgan M, Stevenson JP, O'Dwyer PJ. Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005 May; 55(5):497-501. PMID: 15711828.
    View in: PubMed
  315. Flaherty KT, Brose M, Schuchter L, Tuveson D, Lee R, Schwartz B, Lathia C, Weber B, O'Dwyer P. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):7507. PMID: 28014896.
    View in: PubMed
  316. Schuchter L, Flaherty K, Davidson R, Cavallaro L, Hendricks M, Deming P, Recio A, Tuveson D. Phase I trial of imatinib and temozolomide in patients with metastatic melanoma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):7572. PMID: 28015924.
    View in: PubMed
  317. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2004 Jul 15; 22(14_suppl):4501. PMID: 28016014.
    View in: PubMed
  318. Redlinger M, Kramer A, Flaherty K, Sun W, Haller D, O'Dwyer PJ. A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3767. PMID: 28014142.
    View in: PubMed
  319. Veronese ML, Flaherty KT, Townsend R, Mosenkis A, Zimmer R, Rosen M, Gallagher M, O'Dwyer PJ. Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2035. PMID: 28015640.
    View in: PubMed
  320. Flaherty KT, Stevenson JP, Redlinger M, Algazy KM, Giatonio B, O'Dwyer PJ. A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine. Cancer Chemother Pharmacol. 2004 May; 53(5):404-8. PMID: 15129676.
    View in: PubMed
  321. Flaherty KT, Malkowicz SB, Vaughn DJ. Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancer. Am J Clin Oncol. 2004 Apr; 27(2):136-9. PMID: 15057152.
    View in: PubMed
  322. Flaherty KT. New molecular targets in melanoma. Curr Opin Oncol. 2004 Mar; 16(2):150-4. PMID: 15075908.
    View in: PubMed
  323. Bilenker JH, Stevenson JP, Flaherty KT, Algazy K, McLaughlin K, Haller DG, Giantonio BJ, Koehler M, Garcia-Vargas JE, O'Dwyer PJ. Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies. Cancer Chemother Pharmacol. 2004 Apr; 53(4):357-60. PMID: 14722734.
    View in: PubMed
  324. Flaherty KT, Stevenson JP, Hahn SM, Redlinger M, O'Dwyer PJ. Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy. Cancer Chemother Pharmacol. 2003 Sep; 52(3):217-22. PMID: 12811513.
    View in: PubMed
  325. Flaherty KT, Stevenson JP, Gallagher M, Giantonio B, Algazy KM, Sun W, Haller DG, O'Dwyer PJ. Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer. Cancer. 2003 Apr 15; 97(8):1985-90. PMID: 12673728.
    View in: PubMed
  326. Tao J, Flaherty K, Bagg A. Unusual hematologic malignancies. Case 1. Hematologic malignancy presenting with diarrhea and bony lesions: systemic mastocytosis. J Clin Oncol. 2002 Sep 01; 20(17):3737-9. PMID: 12202674.
    View in: PubMed
  327. Flaherty KT, Stevenson JP, O'Dwyer PJ. Antisense therapeutics: lessons from early clinical trials. Curr Opin Oncol. 2001 Nov; 13(6):499-505. PMID: 11673691.
    View in: PubMed
  328. Lynch JP, White E, Flaherty K. Corticosteroids in idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2001 Sep; 7(5):298-308. PMID: 11584180.
    View in: PubMed
  329. Lynch JP, Wurfel M, Flaherty K, White E, Martinez F, Travis W, Raghu G. Usual interstitial pneumonia. Semin Respir Crit Care Med. 2001 Aug; 22(4):357-86. PMID: 16088686.
    View in: PubMed
  330. Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest. 1998 Sep; 114(3):801-7. PMID: 9743170.
    View in: PubMed
  331. Zurawski SM, Vega F, Doyle EL, Huyghe B, Flaherty K, McKay DB, Zurawski G. Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor. EMBO J. 1993 Dec 15; 12(13):5113-9. PMID: 8262055; PMCID: PMC413773.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Flaherty's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_